Texas Ozempic, Wegovy & Mounjaro Muscle Loss Attorneys — ENDO 2026 Study Confirms GLP-1 Sarcopenia Risk: 753-Patient NIH Analysis Shows Daily Steps Drop from 5,047 to 4,487 and Lean-Mass Wasting, We Hold Novo Nordisk and Eli Lilly Accountable Under Texas’s 2-Year Statute (§16.003), Preserve Fitbit and Apple Health Data Before the 90-Day Auto-Delete, Lupe Peña the Former Insurance-Defense Insider Battles Their Adjusters, Recovery Ranges $75K to $8M+, Texas DTPA Treble Damages Available — Free 24/7 Consultation, No Fee Unless We Win, Hablamos Español, 1-888-ATTY-911
The Moment You Found This Study, You Already Knew You started the medication because your doctor said it would help. Maybe it was Ozempic for type 2 diabetes. Maybe it was Wegovy or Zepbound for weight loss. Maybe you answered an ad, clicked a telehealth link, filled out a five-minute questionnaire, and had a prescription in your hand the same afternoon. The pounds came off. The number on the scale moved. And somewhere along the way, you started feeling weaker. You stopped taking the stairs. The grocery bags got heavier. You told yourself it was just getting older, just the calorie deficit, just your body adjusting. Then maybe you fell. Maybe your balance shifted and your hand found the wall just in time. Maybe your doctor looked at a clean blood test, told you that you were doing great, and sent you home. Maybe a family member watched you struggle to stand from a chair and asked, quietly, whether the medication was the reason. Then you found the ENDO 2026 study. Seven hundred and fifty-three people just like you. Daily steps dropping from 5,047 to 4,487. Moderate-to-vigorous activity falling from 28 minutes a day to 22. Lean muscle mass —…